Axinn Team Prevails for Alvogen in Suboxone Antitrust Litigation
August 26, 2020
In another victory on behalf of Axinn’s client Alvogen, a district court affirmed a previous court ruling that both Alvogen and Dr. Reddy’s Laboratories can move forward with antitrust counterclaims against Indivior. The counterclaims arise from a dispute over generic versions of Suboxone, Indivior’s opioid addiction treatment. The Axinn team included Matt Becker and Ted Mathias.
To subscribe to our publications, click here.
Featured Insights
Featured Insights
IBA Annual Conference 2025
Speaking Engagement
Antitrust
GCR Live: Global Merger Control 2025
Speaking Engagement
Antitrust
Thomson Reuters 24th Annual Law Firm COO & CFO Forum
Speaking Engagement
LegalNEXT 2025
Speaking Engagement
Antitrust
Informa Antitrust Texas 2025
Speaking Engagement
Antitrust
ACI Forum on Pharma & Biotech Patent Litigation USA 2025
Speaking Engagement
Intellectual Property
MCCA Gala 2025
Sponsorship
Antitrust
Axinn Honored at the 2025 Transform Awards North America
Awards & Recognitions
Antitrust 101: Trial-Minded Antitrust Discovery
Webinar
Antitrust
Be Careful What You Wish For: Class Action Waivers and Arbitration Agreements Can Create Headaches if Not Carefully Drafted
Axinn Viewpoints
Litigation & Trials